戈利木单抗（抗TNF单克隆抗体）：我们目前的进展情况。
Golimumab (anti-TNF monoclonal antibody): where we stand today.
作者信息
Melo Ana Teresa, Campanilho-Marques Raquel, Fonseca João Eurico
机构信息
Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.
出版信息
Hum Vaccin Immunother. 2021 Jun 3;17(6):1586-1598. doi: 10.1080/21645515.2020.1836919. Epub 2020 Dec 28.
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inflammation. It is approved for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Nonradiographic axial Spondyloarthritis, Juvenile Idiopathic Arthritis, and Ulcerative Colitis. Clinical trials are also being conducted in other conditions. This review charts the clinical development of golimumab and outlines the data that support its potential use across several Immune-mediated inflammatory diseases.
肿瘤坏死因子（TNF）是一种促炎细胞因子，其过度表达与几种慢性免疫介导的炎症性疾病的病理生理学有关。生物疗法，如TNF抑制剂，一直在彻底改变这些疾病的病程。戈利木单抗是一种转基因抗TNF单克隆抗体，主要通过靶向和中和TNF发挥作用，从而预防炎症。它被批准用于治疗类风湿性关节炎、银屑病关节炎、强直性脊柱炎、非放射性轴性脊柱关节炎、幼年特发性关节炎和溃疡性结肠炎。目前也正在对其他病症进行临床试验。本综述阐述了戈利木单抗的临床开发情况，并概述了支持其在多种免疫介导的炎症性疾病中潜在应用的数据。
Zotero 插件